Expansion of aortic aneurysms is reduced by propranolol in a hypertensive rat model

Slaiby, Jeffrey M.; Ricci, Michael A.; Gadowski, Gregory R.; Hendley, Edith D.; Pilcher, David B.

doi:10.1016/0741-5214(94)90004-3

Cited by 57 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given that a number of studies have found that hypertension is associated with the development of AAA, it is not surprising that antihypertensive therapies have been postulated as a potential medication for AAA. 64 One of the earliest groups of drugs to be tested for any association with AAA growth or rupture were beta-blockers, but although laboratory models 65,66 provided encouraging evidence of a beneficial effect this has not translated convincingly into the general AAA population, 67 although some benefit has been seen in patients with Marfan syndrome. 68 Angiotensin converting enzyme (ACE) inhibitors are also thought to provide benefit to patients with AAA [69][70][71] but there is little evidence on their relationship with rupture and growth rates, 64,72 and there is some evidence to suggest that the use of ACE inhibitors may be harmful in these patients.…”

Section: Medical Therapymentioning

confidence: 99%

The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy.

Brown

Powell²,

Thompson³

et al. 2012

Health Technol Assess

206

170

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects...

show abstract

Section: Medical Therapymentioning

confidence: 99%

The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy.

Brown

Powell²,

Thompson³

et al. 2012

Health Technol Assess

206

170

View full text Add to dashboard Cite

show abstract

“…1,9 Several factors have been involved in the development and enlargement of AA in heart transplant recipients: improved cardiac output 1,9 and new or worsened systemic hypertension 1,9 after transplantation, and an increase in shear stress of the aortic wall, contributing to aneurysm formation and rupture. [10][11][12] Immunosuppresive agents such as cyclosporine and steroids have been shown to cause hypertension. 8,13 Moreover, steroid therapy has been associated with the development and rupture of AA in several experimental models 7,14 and with the formation of aneurysms in patients receiving steroids.…”

Section: Discussionmentioning

confidence: 99%

Thoracoabdominal Aortic Aneurysm Repair in Cardiac Transplant Recipients

Segura

Fernandez²,

Rábago

et al. 2000

Annals of Vascular Surgery

View full text Add to dashboard Cite

“…With the evolution of the animal models of AAA disease, additional studies of propranolol in elastase-induced AAA in rats without previous hypertension did not affect aneurysm development [70]. However, they were able to demonstrate that propranolol decreased the size of AAA diameter in hypertensive rats without significantly altering blood pressure.…”

Section: β-Adrenergic Receptorsmentioning

confidence: 95%

Pharmacological targets in the treatment of abdominal aortic aneurysms

Bergoeing

Thompson

Curci

2006

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

The natural history of an abdominal aortic aneurysm (AAA) is of progressive aortic wall degeneration occurring over the course of many years, ultimately, culminating in loss of structural integrity and fatal aortic rupture. Although surgical exclusion of an aneurysm can effectively prevent aortic rupture in large aneurysms, small aneurysms are generally completely asymptomatic and are very unlikely to rupture. Further, AAA can be easily diagnosed with noninvasive testing; thus, small aneurysms present an excellent opportunity for disease-modifying pharmacological intervention. Research over the past two decades has defined many of the mechanisms which result in aortic matrix degeneration in both human tissue and particularly within animal models. This has resulted in the identification of several potential targets for pharmacological intervention. Drugs directed at inhibition of the inflammatory process and matrix degrading enzymes have been successful in multiple animal models, and early evidence now suggests that disease modification with some of these agents may be successful in slowing AAA growth in humans as well. The future of AAA therapy, however, may belong to agents which can induce aneurysm regression and to delivery methods which specifically target affected arterial tissue.

show abstract

Expansion of aortic aneurysms is reduced by propranolol in a hypertensive rat model

Cited by 57 publications

References 13 publications

The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy.

The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy.

Thoracoabdominal Aortic Aneurysm Repair in Cardiac Transplant Recipients

Pharmacological targets in the treatment of abdominal aortic aneurysms

Contact Info

Product

Resources

About